STRATA Skin Sciences, Inc.
SSKN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.36 | -0.01 | 0.22 | -0.05 |
| FCF Yield | -1.17% | -1.97% | -0.68% | 0.18% |
| EV / EBITDA | -587.00 | -152.82 | -187.21 | -42.27 |
| Quality | ||||
| ROIC | -10.42% | -13.07% | -10.36% | -18.63% |
| Gross Margin | 60.38% | 56.19% | 53.54% | 60.12% |
| Cash Conversion Ratio | 0.04 | 0.78 | 0.23 | -0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.23% | -2.86% | -2.87% | -2.46% |
| Free Cash Flow Growth | 42.45% | -151.00% | -476.38% | 154.67% |
| Safety | ||||
| Net Debt / EBITDA | -53.39 | -14.99 | -15.42 | -3.23 |
| Interest Coverage | -3.73 | -4.53 | -4.15 | -8.21 |
| Efficiency | ||||
| Inventory Turnover | 0.90 | 1.04 | 1.19 | 1.70 |
| Cash Conversion Cycle | 48.89 | 55.04 | 61.69 | 44.96 |